Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stromal cell cultures

Cytotherapy

Volumn 15, Issue 12, 2013, Pages 1458-1468

  Mojica Henshaw, Mariluz P ^a   jacobson, Pam ^a   Morris, Julie ^a   Kelley, Linda ^b   Pierce, Jan ^a   Boyer, Michael ^a   Reems, Jo Anna ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Cryo Cell International Inc   (United States)

Author keywords

Blood platelets; Cell proliferation; Growth factors; Mesenchymal stromal cells; Platelet rich plasma

Indexed keywords

GROWTH FACTOR;

ADIPOGENESIS; ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CELL CULTURE; CELL GROWTH; CELL LYSATE; CELL PROLIFERATION; CHONDROGENESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; MESENCHYMAL STROMA CELL; NONHUMAN; PLATELET LYSATE SERUM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

BLOOD PLATELETS; CELL PROLIFERATION; GROWTH FACTORS; MESENCHYMAL STROMAL CELLS; PLATELET-RICH PLASMA;

ADIPOSE TISSUE; ANIMALS; CATTLE; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CULTURE MEDIA; FLOW CYTOMETRY; HUMANS; MESENCHYMAL STROMAL CELLS; PLATELET-RICH PLASMA; SERUM;

EID: 84887103459     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.06.014     Document Type: Article

References (47)

1. Freshney R.I. Culture of animal cells: a manual of basic technique and specialized applications 2010, John Wiley & Sons, Inc, Hoboken, NJ. 6th ed.
2. Lennon D.P., Caplan A.I. Isolation of human marrow-derived mesenchymal stem cells. Exp Hematol 2006, 34:1604-1605.
3. Shahdadfar A., Fronsdal K., Haug T., Reinholt F.P., Brinchmann J.E. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005, 23:1357-1366.
4. Spees J.L., Gregory C.A., Singh H., Tucker H.A., Peister A., Lynch P.J., et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004, 9:747-756.
5. Zheng X., Baker H., Hancock W.S., Fawaz F., McCaman M., Pungor E. Proteomic analysis for the assessment of different lots of fetal bovine serum as a raw material for cell culture. Part IV. Application of proteomics to the manufacture of biological drugs. Biotechnol Prog 2006, 22:1294-1300.
6. Bernardo M.E., Cometa A.M., Pagliara D., Vinti L., Rossi F., Cristantielli R., et al. Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol 2011, 24:73-81.
7. Sensebe L., Bourin P., Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 2011, 22:19-26.
8. Lennon D.P., Haynesworth S.E., Young R.G., Dennis J.E., Caplan A.I. Achemically defined medium supports in vitro proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells. Exp Cell Res 1995, 219:211-222.
9. Ng F., Boucher S., Koh S., Sastry K.S., Chase L., Lakshmipathy U., et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008, 112:295-307.
10. Lund P., Pilgaard L., Duroux M., Fink T., Zachar V. Effect of growth media and serum replacements on the proliferation and differentiation of adipose-derived stem cells. Cytotherapy 2009, 11:189-197.
11. Jung S., Sen A., Rosenberg L., Behie L.A. Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells. Cytotherapy 2010, 12:637-657.
12. Chase L.G., Lakshmipathy U., Solchaga L.A., Rao M.S., Vemuri M.C. Anovel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther 2010, 1:8.
13. Mimura S., Kimura N., Hirata M., Tateyama D., Hayashida M., Umezawa A., et al. Growth factor-defined culture medium for human mesenchymal stem cells. Int J Dev Biol 2011, 55:181-187.
14. Agata H., Watanabe N., Ishii Y., Kubo N., Ohshima S., Yamazaki M., et al. Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. Biochem Biophys Res Commun 2009, 382:353-358.
15. Abdallah B.M., Haack-Sorensen M., Fink T., Kassem M. Inhibition of osteoblast differentiation but not adipocyte differentiation of mesenchymal stem cells by sera obtained from aged females. Bone 2006, 39:181-188.
16. Kocaoemer A., Kern S., Kluter H., Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007, 25:1270-1278.
17. Pytlik R., Stehlik D., Soukup T., Kalbacova M., Rypacek F., Trc T., et al. The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering. Biomaterials 2009, 30:3415-3427.
18. Poloni A., Maurizi G., Serrani F., Mancini S., Discepoli G., Tranquilli A.L., et al. Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate. Cell Prolif 2012, 45:66-75.
19. Doucet C., Ernou I., Zhang Y., Llense J.R., Begot L., Holy X., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. JCell Physiol 2005, 205:228-236.
20. Muller I., Kordowich S., Holzwarth C., Spano C., Isensee G., Staiber A., et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006, 8:437-444.
21. Bernardo M.E., Avanzini M.A., Perotti C., Cometa A.M., Moretta A., Lenta E., et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. JCell Physiol 2007, 211:121-130.
22. Capelli C., Domenghini M., Borleri G., Bellavita P., Poma R., Carobbio A., et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007, 40:785-791.
23. Lange C., Cakiroglu F., Spiess A.N., Cappallo-Obermann H., Dierlamm J., Zander A.R. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. JCell Physiol 2007, 213:18-26.
24. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion (Paris) 2007, 47:1436-1446.
25. Carrancio S., Lopez-Holgado N., Sanchez-Guijo F.M., Villaron E., Barbado V., Tabera S., et al. Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. Exp Hematol 2008, 36:1014-1021.
26. Perez-Ilzarbe M., Diez-Campelo M., Aranda P., Tabera S., Lopez T., del C.C., et al. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion (Paris) 2009, 49:1901-1910.
27. Bieback K., Hecker A., Kocaomer A., Lannert H., Schallmoser K., Strunk D., et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
28. Lucarelli E., Beccheroni A., Donati D., Sangiorgi L., Cenacchi A., Del Vento A.M., et al. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials 2003, 24:3095-4100.
29. Huang Q., Xu T., Wang G.Y., Huang J.F., Xia H., Yin R., et al. Species-specific identification of ruminant components contaminating industrial crude porcine heparin using real-time fluorescent qualitative and quantitative PCR. Anal Bioanal Chem 2012, 402:1625-1634.
30. Bottio T., Pittarello G., Bonato R., Fagiolo U., Gerosa G. Life threatening anaphylactic shock caused by porcine heparin intravenous infusion during mitral valve repair. JThorac Cardiovasc Surg 2003, 126:1194-1195.
31. Dominici M., Le B.K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
32. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. Arandomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction. JAm Coll Cardiol 2009, 54:2277-2286.
33. Otsuru S., Gordon P.L., Shimono K., Jethva R., Marino R., Phillips C.L., et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 2012, 120:1933-1941.
34. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
35. Connick P., Kolappan M., Crawley C., Webber D.J., Patani R., Michell A.W., et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012, 11:150-156.
36. von Bonin M., Stolzel F., Goedecke A., Richter K., Wuschek N., Holig K., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
37. Lucchini G., Introna M., Dander E., Rovelli A., Balduzzi A., Bonanomi S., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010, 16:1293-1301.
38. Harada A., Tatsuno K., Kikuchi T., Takahashi Y., Sai S., Murakami Y., et al. Use of bovine lung heparin to obviate anaphylactic shock caused by porcine gut heparin. Ann Thorac Surg 1990, 49:826-827.
39. Liu H., Zhang Z., Linhardt R.J. Lessons learned from the contamination of heparin. Nat Prod Rep 2009, 26:313-321.
40. Sakr Y. Heparin-induced thrombocytopenia in the ICU: an overview. Crit Care 2011, 15:211-219.
41. Seeger F.H., Rasper T., Fischer A., Muhly-Reinholz M., Hergenreider E., Leister D.M., et al. Heparin disrupts the CXCR4/SDF1 axis and impairs the functional capacity of bone marrow-derived mononuclear cells used for cardiovascular repair. Circ Res 2012, 111:854-862.
42. Schallmoser K., Strunk D. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. JVis Exp 2009, 32:e1523.
43. Fekete N., Gadelorge M., Furst D., Maurer C., Dausend J., Fleury-Cappellesso S., et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 2012, 14:540-554.
44. Dry H., Jorgenson K., Ando W., Hart D.A., Frank C.B., Sen A. Effect of calcium on the proliferation kinetics of synovium-derived mesenchymal stromal cells. Cytotherapy 2013, 15:805-819.
45. Millar C.M., Makris M. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products. Br J Haematol 2012, 158:442-452.
46. Horn P., Bokermann G., Cholewa D., Bork S., Walenda T., Koch C., et al. Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy 2010, 12:888-898.
47. Lohmann M., Walenda G., Hemeda H., Joussen S., Drescher W., Jockenhoevel S., et al. Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS One 2012, 5:e37839.